Business Description
Verrica Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US92511W1080
Description
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.49 | |||||
| Equity-to-Asset | -1.03 | |||||
| Debt-to-Equity | -1.38 | |||||
| Debt-to-EBITDA | -0.63 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -18.88 | |||||
| Beneish M-Score | -4.96 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 4.5 | |||||
| 3-Year EPS without NRI Growth Rate | 5.9 | |||||
| 3-Year FCF Growth Rate | 12.2 | |||||
| 3-Year Book Growth Rate | -28.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 48.59 | |||||
| Future 3-5Y Total Revenue Growth Rate | 92.91 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.52 | |||||
| 9-Day RSI | 35.33 | |||||
| 14-Day RSI | 36.94 | |||||
| 6-1 Month Momentum % | -85.54 | |||||
| 12-1 Month Momentum % | -83.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.34 | |||||
| Quick Ratio | 1.22 | |||||
| Cash Ratio | 1.09 | |||||
| Days Inventory | 277.93 | |||||
| Days Sales Outstanding | 249.89 | |||||
| Days Payable | 276.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.6 | |||||
| Shareholder Yield % | -58.38 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.08 | |||||
| Operating Margin % | -815.51 | |||||
| Net Margin % | -922.81 | |||||
| FCF Margin % | -640.81 | |||||
| ROE % | -2619.46 | |||||
| ROA % | -128.78 | |||||
| ROIC % | -467.81 | |||||
| ROC (Joel Greenblatt) % | -1764.25 | |||||
| ROCE % | -156.8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.28 | |||||
| EV-to-EBIT | -1.1 | |||||
| EV-to-EBITDA | -1.11 | |||||
| EV-to-Revenue | 9 | |||||
| EV-to-Forward-Revenue | 6.95 | |||||
| EV-to-FCF | -1.39 | |||||
| Earnings Yield (Greenblatt) % | -90.91 | |||||
| FCF Yield % | -101.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Verrica Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 8.547 | ||
| EPS (TTM) (€) | -1.685 | ||
| Beta | 3.09 | ||
| Volatility % | 124.47 | ||
| 14-Day RSI | 36.94 | ||
| 14-Day ATR (€) | 0.058487 | ||
| 20-Day SMA (€) | 0.868 | ||
| 12-1 Month Momentum % | -83.29 | ||
| 52-Week Range (€) | 0.58 - 8.72 | ||
| Shares Outstanding (Mil) | 90.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Verrica Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Verrica Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Verrica Pharmaceuticals Inc Frequently Asked Questions
What is Verrica Pharmaceuticals Inc(FRA:1NE)'s stock price today?
The current price of FRA:1NE is €0.62. The 52 week high of FRA:1NE is €8.72 and 52 week low is €0.58.
When is next earnings date of Verrica Pharmaceuticals Inc(FRA:1NE)?
The next earnings date of Verrica Pharmaceuticals Inc(FRA:1NE) is 2025-02-28 Est..
Does Verrica Pharmaceuticals Inc(FRA:1NE) pay dividends? If so, how much?
Verrica Pharmaceuticals Inc(FRA:1NE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers